Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters

Abstract

Background/aim: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, whichhas been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationshipwith metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS).Materials and methods: Fifty-three patients and 26 healthy controls were included in this study. Serum adropin levels, fasting bloodglucose, fasting serum insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceridelevels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels. Results: Serum adropin levels were 2.94 ± 0.56 ng/mL in psoriatic patients without MetS, 2.49 ± 0.77 ng/mL in psoriasis patients withMetS, and 3.37 ± 0.71 ng/mL in the control group. Multivariate logistic regression analysis was used to evaluate adropin decreases inpsoriasis patients as an independent predictor of the presence of MetS. Conclusion: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease wasmore prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development ofMetS in psoriasis patients.